The present study demonstrated that darolutamide decreases SREBP1 expression to inhibit fatty acid synthase (FASN) transcription, which induces lipid peroxidation and ferroptosis onset, leading to suppression of PCa tumorigenesis. This evidence concerns the gene FASN and posterior cortical atrophy.